VTGN SHAREHOLDER ACTION: Faruqi & Faruqi, LLP Reminds Vistagen (VTGN) Investors of the Securities Class Action Lawsuit Deadline on March 16, 2026

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. related to alleged violations of federal securities laws during the Phase 3 PALISADE-3 trial of fasedienol, a treatment for social anxiety disorder [4]. Group 1: Legal Investigation - The law firm is encouraging Vistagen investors who suffered losses exceeding $50,000 to contact them for discussing legal options [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Vistagen and its executives made false or misleading statements and failed to disclose material adverse facts regarding their clinical trial [4]. Group 2: Firm Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. - The firm has offices in New York, Pennsylvania, California, and Georgia, indicating a broad operational footprint [3]. Group 3: Whistleblower Encouragement - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Vistagen's conduct [6].